Harbin Gloria Pharmaceuticals Stock Forum

The company's low P/S ratio could be due to declining revenue, posing a challenge to maintain its share price. Market participants might be accepting this, anticipating no future revenue surprises.

Despite a lower P/S ratio than industry peers due to shrinking revenue, this may decrease if the company doesn't remedy its growth. Conservatism in stock prices is expected barring significant changes. Even the recent share price surge didn't raise the P/S to the industry median.

Surge could hint at a positive shift, but history of dwindling income and constant negative returns pose concerns. Numerically cautious investors might fret over this stock. Contrarians, despite recent underperformance, may explore this for a possible turnaround.